SCHEMBL1027228

SCHEMBL1027228

OC1CCC(O)N1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18721401 1.00
SCHEMBL1651050 0.64
SCHEMBL19346764 0.64
SCHEMBL11282501 0.63
SCHEMBL16869294 0.61
SCHEMBL23262204 0.58 LMNA (0.57)
SCHEMBL16264920 0.56 GAA (0.35)
SCHEMBL8611 0.55
SCHEMBL21379879 0.54
SCHEMBL20613480 0.54

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023143263-A1 ANTIBODY AGAINST HER3, CONJUGATE AND USE THEREOF 苏州宜联生物医药有限公司 2023-08-03 WO disclosed
EP-3053600-B1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN INC (US) 2020-01-29 EP disclosed
EP-2277510-B1 Controlled release preparation TAKEDA PHARMACEUTICALS CO (JP) 2018-12-26 EP disclosed
EP-2275088-B2 Method for producing granules TAKEDA PHARMACEUTICALS CO (JP) 2018-09-26 EP disclosed
US-9688627-B2 Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions CAYMAN CHEMICAL COMPANY, INC. (US) 2017-06-27 US disclosed
EP-1602362-B1 DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE TAKEDA PHARMACEUTICAL (JP) 2016-09-28 EP disclosed
US-20160128945-A1 CONTROLLED RELEASE PREPARATION TAKEDA PHARMACEUTICAL (JP) 2016-05-12 US disclosed
EP-2275088-B1 Method for producing granules TAKEDA PHARMACEUTICAL (JP) 2015-09-02 EP disclosed
US-8980322-B2 Controlled release composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-03-17 US disclosed
US-20150072015-A1 METHOD FOR PRODUCING GRANULES TAKEDA PHARMACEUTICAL (JP) 2015-03-12 US disclosed
US-20070141137-A1 Stable capsule preparation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-21 US disclosed
US-20060293371-A1 Prodrug and process for producing the same TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) 2006-12-28 US disclosed
EP-1721604-A1 STABLE CAPSULE PREPARATION Takeda Pharmaceutical Company Limited (JP) 2006-11-15 EP disclosed
US-20060177509-A1 Controlled release composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-08-10 US disclosed
US-20060159760-A1 Drug composition having active ingredient adhered at high concentration to spherical core AOYAMA & PARTNERS 2006-07-20 US disclosed
US-20060013868-A1 Controlled release preparation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-19 US disclosed
EP-1607088-A1 CONTROLLED RELEASE COMPOSITION Takeda Pharmaceutical Company Limited (JP) 2005-12-21 EP disclosed
EP-1602362-A1 DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE Takeda Pharmaceutical Company Limited (JP) 2005-12-07 EP disclosed
US-20050222210-A1 Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-06 US disclosed
EP-1514870-A1 PRODRUG AND PROCESS FOR PRODUCING THE SAME Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed